Ivabradine has been approved by NICE (TA 267)1 as an option for treating chronic heart failure following specialist initiation in patients with chronic, stable heart failure (NYHA class II-IV), left ventricular systolic dysfunction (LVEF 35% or less) and who are in sinus rhythm with a heart rate of 75 beats per minute or more.
